Trial reportBritish journal of haematology2019
Lenalidomide plus rituximab (R
Trial report in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01996865 (A Phase 3B Randomized Study of Lenalidomide), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.Haematologica · 2024Trial
- Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.Future oncology (London, England) · 2026Article
- Review
- SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Review
- Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.Current treatment options in oncology · 2025Review
- Primary choroidal lymphoma with extrascleral extension and bone marrow involvement: a case report.Frontiers in medicine · 2025Article
- Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.Hematological oncology · 2024Article
- Advances in the treatment of relapsed/refractory marginal zone lymphoma.Frontiers in oncology · 2024Review
- Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.Oncology research · 2024Article
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Review
- Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (VCurrent oncology (Toronto, Ont.) · 2022Article
- The EHA Research Roadmap: Malignant Lymphoid Diseases.HemaSphere · 2022Article
- An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.Blood advances · 2022Article
- Review
- Article
- Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review.The Journal of international medical research · 2022Review
- Marginal zone lymphoma: present status and future perspectives.Haematologica · 2022Article
- Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.Frontiers in immunology · 2022Review
- Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Lack of consensus for first-line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first-line lenalidomide and rituximab (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.